Global Fibroblast Cells Market By Product Type (Human Dermal Fibroblasts, Dermal Fibroblasts matched with Subcutaneous Preadipocytes and Others); By Type (Tissue Specific Fibroblasts (Skin, Mammary, Lung, Kidney, Muscle, Others), Disease-Specific Fibroblasts (Astrocytoma, Amyotrophic Lateral Sclerosis (ALS), Wound Healing, Arteriovenous Malformation (AVM) Patient, Duchenne Muscular Dystrophy (DMD) Patient, Diabetes, Guillain-Barre Syndrome (GBS) Patient, Glioblastoma Patient, Huntington's Disease (HD) Patient, Legg-Calve-Perthes Syndrome Patient, Mucopolysaccharidosis Patient, Neurofibromatosis Patient, Parkinson's Disease Patient, Psoriasis Patient, Rheumatoid Arthritis Patient, Systemic Lupus Erythematosus (SLE), Transverse Myelitis Patient, Others), and Serum-free Fibroblast Culture Medium); By Application (Adults and Neonatal); By End Users (Hospitals, Clinics, Research and Academic Institutes, and Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spa
Industry Trends
Fibroblasts cells are a practical alternative to mesenchymal stem cells as they are easily collected in large numbers from various biological wastes. In vitro expansion of fibroblasts is substantially easier given the shorter doubling time compared to typical mesenchymal stem cells and robustness of these cells in tissue culture, thus reducing the cost of production. Fibroblasts cells may be utilized as a more practical and potentially effective cell therapy than mesenchymal stem cells, which is driving the demand of fibroblast cells market.
Mesenchymal stem cells generation often involves isolation and in vitro growth of the cellular product. In contrast, fibroblasts may be grown without the need for isolation of specific subtypes of cells. The companies operating in the fibroblast cells market are embarking on technological innovation to increase their market prominence. For instance, in May 2019, SpinalCyte, LLC, a clinical-stage regenerative medicine corporation focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), announced a new complete resource to increase awareness of the potential benefits of fibroblasts and offers a rising knowledge base for this promising regenerative medicine technology. SpinalCyte introduced an initiative to highlight advances in fibroblast technology.
The impact of the COVID-19 pandemic on the fibroblast cells market is expected to be significant as most of the companies have been focusing on the development of cell-based therapies for COVID-19 treatment. For instance, in July 2020, FibroGenesis launched new data supporting the use of its PneumoBlast product (fibroblast cell therapy) in the battle against COVID-19. With the use of a widely accepted bleomycin model of lung scarring (fibrosis), scientists of FibroGenesis have demonstrated the administration and usage of PneumoBlast induced a 51% reduction of lung fibrosis. Notably, when PneumoBlast was compared head-to-head with bone marrow-derived mesenchymal stem cells (BMSCs) for COVID-19, PneumoBlast was 221% more effective.
In terms of revenue, the global fibroblast cells market was is growing at a CAGR of 8.92% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Fibroblast Cells Market Revenue & Forecast, (US$ Million), 2015 – 2030
Product Type Outlook:
The global fibroblast cells market has been segmented into human dermal fibroblasts, dermal fibroblasts matched with subcutaneous preadipocytes and others based on the product type. The human dermal fibroblasts segment holds a considerable share of the global fibroblast cells market in 2021. Human dermal fibroblasts are the most accessible cells in the skin that have gained substantial attention in cell therapy. Applying dermal fibroblasts' regenerative capacity introduces new patterns to develop cell-based therapies with an aim to treat skin disorders. Dermal fibroblasts originate from mesenchymal cells and they are situated within the dermis. These cells are mainly responsible for synthesizing glycosaminoglycans, collagens, and extracellular matrix components supporting the skin's structural integrity. Several preclinical studies suggested that allogeneic and autologous dermal fibroblasts provide widespread and beneficial applications for burn ulcers, wound healing, and inherited skin disorders. Hence, generating induced pluripotent stem cells (iPSCs) from fibroblasts and gene-edited fibroblasts are the promising approaches for treating skin conditions.
Type Outlook:
Based on the type segment, the global fibroblast cells market has been segmented into tissue-specific fibroblasts, disease-specific fibroblasts, and serum-free fibroblast culture medium. In 2021, the tissue-specific fibroblasts segment registered for the major share of the global fibroblast cells market. Fibroblasts have the capacity to synthesize adhesive components of the skin basement membrane zone, including C7, as well as potentially augment wound healing. This cell therapy's several benefits and high success rate are driving its growth.
Region Outlook:
North America region dominated the global fibroblast cells market in 2021, followed by Europe, Asia Pacific, Middle East & Africa, Latin America, respectively. The existence of a strict regulatory framework to promote fibroblast cells therapy development, key industry players, and leading universities that support the research activities in the United States are driving the regional market. Furthermore, the high expenditure capacity of American consumers and the availability of well-established health care facilities are some of the major factors supporting the demand.
Competitive Landscape
The report provides both qualitative and quantitative research of the global fibroblast cells market and provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. The report studies their global presence, competitors, service offerings and specification for each company, amongst others.
Some of the key players operating in the global fibroblast cells market are listed below:
- Axol Bioscience Ltd.
- Cell Applications, Inc.
- FibroGenesis.
- Merck KGaA, Darmstadt
- Novus Biologicals
- Ohr Pharma + NewBase Therapeutics
- ThermoFisher Scientific
- ZenBio, Inc.
- Other Market Participants
Global Fibroblast Cells Market:
By Product Type
- Human Dermal Fibroblasts
- Dermal Fibroblasts matched with Subcutaneous Preadipocytes
- Others
By Type
- Tissue-Specific Fibroblasts
- Skin
- Mammary
- Lung
- Kidney
- Muscle
- Others
- Disease-specific Fibroblasts
- Astrocytoma
- Amyotrophic Lateral Sclerosis (ALS)
- Wound Healing
- Arteriovenous Malformation (AVM) Patient
- Duchenne Muscular Dystrophy (DMD) Patient
- Diabetes
- Guillain-Barre Syndrome (GBS) Patient
- Glioblastoma Patient
- Huntington's Disease (HD) Patient
- Legg-Calve-Perthes Syndrome Patient
- Mucopolysaccharidosis Patient
- Neurofibromatosis Patient
- Parkinson's Disease Patient
- Psoriasis Patient
- Rheumatoid Arthritis Patient
- Systemic Lupus Erythematosus (SLE)
- Transverse Myelitis Patient
- Others
- Serum-free Fibroblast Culture Medium
By Application
- Adults
- Neonatal
By End Users
- Hospitals
- Clinics
- Research and Academic Institutes
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 – 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Fibroblast Cells Market
6. Market Synopsis: Fibroblast Cells Market
7. Fibroblast Cells Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in Fibroblast Cells Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators: Fibroblast Cells Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Fibroblast Cells Market
8. Global Fibroblast Cells Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global Fibroblast Cells Market Revenue (US$ Mn)
8.2. Global Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
8.2.1. Human Dermal Fibroblasts
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 – 2021
8.2.1.3. Market Forecast, 2022 – 2030
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market Estimation, 2015 – 2021
8.2.1.5.1.2. Market Forecast, 2022 – 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market Estimation, 2015 – 2021
8.2.1.5.2.2. Market Forecast, 2022 – 2030
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market Estimation, 2015 – 2021
8.2.1.5.3.2. Market Forecast, 2022 – 2030
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market Estimation, 2015 – 2021
8.2.1.5.4.2. Market Forecast, 2022 – 2030
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market Estimation, 2015 – 2021
8.2.1.5.5.2. Market Forecast, 2022 – 2030
8.2.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 – 2021
8.2.2.3. Market Forecast, 2022 – 2030
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market Estimation, 2015 – 2021
8.2.2.5.1.2. Market Forecast, 2022 – 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market Estimation, 2015 – 2021
8.2.2.5.2.2. Market Forecast, 2022 – 2030
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market Estimation, 2015 – 2021
8.2.2.5.3.2. Market Forecast, 2022 – 2030
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market Estimation, 2015 – 2021
8.2.2.5.4.2. Market Forecast, 2022 – 2030
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market Estimation, 2015 – 2021
8.2.2.5.5.2. Market Forecast, 2022 – 2030
8.2.3. Others
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 – 2021
8.2.3.3. Market Forecast, 2022 – 2030
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market Estimation, 2015 – 2021
8.2.3.5.1.2. Market Forecast, 2022 – 2030
8.2.3.5.2. Europe
8.2.3.5.2.1. Market Estimation, 2015 – 2021
8.2.3.5.2.2. Market Forecast, 2022 – 2030
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market Estimation, 2015 – 2021
8.2.3.5.3.2. Market Forecast, 2022 – 2030
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market Estimation, 2015 – 2021
8.2.3.5.4.2. Market Forecast, 2022 – 2030
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market Estimation, 2015 – 2021
8.2.3.5.5.2. Market Forecast, 2022 – 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Product Type
9. Global Fibroblast Cells Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
9.2.1. Tissue Specific Fibroblasts (Definition, Market Estimation and Penetration, 2015 – 2021, Market Estimation (2015 – 2021), Market Forecast (2022 – 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Skin, Mammary, Lung, Kidney, Muscle, Others)
9.2.1.1. Skin
9.2.1.2. Mammary
9.2.1.3. Lung
9.2.1.4. Kidney
9.2.1.5. Muscle
9.2.1.6. Others
9.2.2. Disease-specific Fibroblasts (Definition, Market Estimation and Penetration, 2015 – 2021, Market Estimation (2015 – 2021), Market Forecast (2022 – 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Astrocytoma, Amyotrophic Lateral Sclerosis (ALS), Wound Healing, Arteriovenous Malformation (AVM) Patient, Duchenne Muscular Dystrophy (DMD) Patient, Diabetes, Guillain-Barre Syndrome (GBS) Patient, Glioblastoma Patient, Huntington's Disease (HD) Patient, Legg-Calve-Perthes Syndrome Patient, Mucopolysaccharidosis Patient, Neurofibromatosis Patient, Parkinson's Disease Patient, Psoriasis Patient, Rheumatoid Arthritis Patient, Systemic Lupus Erythematosus (SLE), Transverse Myelitis Patient, Others)
9.2.2.1. Astrocytoma
9.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
9.2.2.3. Wound Healing
9.2.2.4. Arteriovenous Malformation (AVM) Patient
9.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
9.2.2.6. Diabetes
9.2.2.7. Guillain-Barre Syndrome (GBS) Patient
9.2.2.8. Glioblastoma Patient
9.2.2.9. Huntington's Disease (HD) Patient
9.2.2.10. Legg-Calve-Perthes Syndrome Patient
9.2.2.11. Mucopolysaccharidosis Patient
9.2.2.12. Neurofibromatosis Patient
9.2.2.13. Parkinson's Disease Patient
9.2.2.14. Psoriasis Patient
9.2.2.15. Rheumatoid Arthritis Patient
9.2.2.16. Systemic Lupus Erythematosus (SLE)
9.2.2.17. Transverse Myelitis Patient
9.2.2.18. Others
9.2.3. Serum-free Fibroblast Culture Medium
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 – 2021
9.2.3.3. Market Forecast, 2022 – 2030
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market Estimation, 2015 – 2021
9.2.3.5.1.2. Market Forecast, 2022 – 2030
9.2.3.5.2. Europe
9.2.3.5.2.1. Market Estimation, 2015 – 2021
9.2.3.5.2.2. Market Forecast, 2022 – 2030
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market Estimation, 2015 – 2021
9.2.3.5.3.2. Market Forecast, 2022 – 2030
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market Estimation, 2015 – 2021
9.2.3.5.4.2. Market Forecast, 2022 – 2030
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market Estimation, 2015 – 2021
9.2.3.5.5.2. Market Forecast, 2022 – 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Type
10. Global Fibroblast Cells Market Analysis and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
10.2.1. Adults
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 – 2021
10.2.1.3. Market Forecast, 2022 – 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015 – 2021
10.2.1.5.1.2. Market Forecast, 2022 – 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015 – 2021
10.2.1.5.2.2. Market Forecast, 2022 – 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 – 2021
10.2.1.5.3.2. Market Forecast, 2022 – 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 – 2021
10.2.1.5.4.2. Market Forecast, 2022 – 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015 – 2021
10.2.1.5.5.2. Market Forecast, 2022 – 2030
10.2.2. Neonatal
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 – 2021
10.2.2.3. Market Forecast, 2022 – 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 – 2021
10.2.2.5.1.2. Market Forecast, 2022 – 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 – 2021
10.2.2.5.2.2. Market Forecast, 2022 – 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 – 2021
10.2.2.5.3.2. Market Forecast, 2022 – 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 – 2021
10.2.2.5.4.2. Market Forecast, 2022 – 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 – 2021
10.2.2.5.5.2. Market Forecast, 2022 – 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Application
11. Global Fibroblast Cells Market Analysis and Forecasts, 2022 – 2030
11.1. Overview
11.2. Global Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
11.2.1. Hospitals
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 – 2021
11.2.1.3. Market Forecast, 2022 – 2030
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market Estimation, 2015 – 2021
11.2.1.5.1.2. Market Forecast, 2022 – 2030
11.2.1.5.2. Europe
11.2.1.5.2.1. Market Estimation, 2015 – 2021
11.2.1.5.2.2. Market Forecast, 2022 – 2030
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market Estimation, 2015 – 2021
11.2.1.5.3.2. Market Forecast, 2022 – 2030
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market Estimation, 2015 – 2021
11.2.1.5.4.2. Market Forecast, 2022 – 2030
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market Estimation, 2015 – 2021
11.2.1.5.5.2. Market Forecast, 2022 – 2030
11.2.2. Clinics
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 – 2021
11.2.2.3. Market Forecast, 2022 – 2030
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market Estimation, 2015 – 2021
11.2.2.5.1.2. Market Forecast, 2022 – 2030
11.2.2.5.2. Europe
11.2.2.5.2.1. Market Estimation, 2015 – 2021
11.2.2.5.2.2. Market Forecast, 2022 – 2030
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market Estimation, 2015 – 2021
11.2.2.5.3.2. Market Forecast, 2022 – 2030
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market Estimation, 2015 – 2021
11.2.2.5.4.2. Market Forecast, 2022 – 2030
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market Estimation, 2015 – 2021
11.2.2.5.5.2. Market Forecast, 2022 – 2030
11.2.3. Research and Academic Institutes
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 – 2021
11.2.3.3. Market Forecast, 2022 – 2030
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market Estimation, 2015 – 2021
11.2.3.5.1.2. Market Forecast, 2022 – 2030
11.2.3.5.2. Europe
11.2.3.5.2.1. Market Estimation, 2015 – 2021
11.2.3.5.2.2. Market Forecast, 2022 – 2030
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market Estimation, 2015 – 2021
11.2.3.5.3.2. Market Forecast, 2022 – 2030
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market Estimation, 2015 – 2021
11.2.3.5.4.2. Market Forecast, 2022 – 2030
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market Estimation, 2015 – 2021
11.2.3.5.5.2. Market Forecast, 2022 – 2030
11.2.4. Others
11.2.4.1. Definition
11.2.4.2. Market Estimation and Penetration, 2015 – 2021
11.2.4.3. Market Forecast, 2022 – 2030
11.2.4.4. Compound Annual Growth Rate (CAGR)
11.2.4.5. Regional Bifurcation
11.2.4.5.1. North America
11.2.4.5.1.1. Market Estimation, 2015 – 2021
11.2.4.5.1.2. Market Forecast, 2022 – 2030
11.2.4.5.2. Europe
11.2.4.5.2.1. Market Estimation, 2015 – 2021
11.2.4.5.2.2. Market Forecast, 2022 – 2030
11.2.4.5.3. Asia Pacific
11.2.4.5.3.1. Market Estimation, 2015 – 2021
11.2.4.5.3.2. Market Forecast, 2022 – 2030
11.2.4.5.4. Middle East and Africa
11.2.4.5.4.1. Market Estimation, 2015 – 2021
11.2.4.5.4.2. Market Forecast, 2022 – 2030
11.2.4.5.5. Latin America
11.2.4.5.5.1. Market Estimation, 2015 – 2021
11.2.4.5.5.2. Market Forecast, 2022 – 2030
11.3. Key Segment for Channeling Investments
11.3.1. By End Users
12. North America Fibroblast Cells Market Analysis and Forecasts, 2022 - 2030
12.1. Overview
12.1.1. North America Fibroblast Cells Market Revenue (US$ Mn)
12.2. North America Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
12.2.1. Human Dermal Fibroblasts
12.2.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
12.2.3. Others
12.3. North America Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
12.3.1. Tissue Specific Fibroblasts
12.3.1.1. Skin
12.3.1.2. Mammary
12.3.1.3. Lung
12.3.1.4. Kidney
12.3.1.5. Muscle
12.3.1.6. Others
12.3.2. Disease-specific Fibroblasts
12.3.2.1. Astrocytoma
12.3.2.2. Amyotrophic Lateral Sclerosis (ALS)
12.3.2.3. Wound Healing
12.3.2.4. Arteriovenous Malformation (AVM) Patient
12.3.2.5. Duchenne Muscular Dystrophy (DMD) Patient
12.3.2.6. Diabetes
12.3.2.7. Guillain-Barre Syndrome (GBS) Patient
12.3.2.8. Glioblastoma Patient
12.3.2.9. Huntington's Disease (HD) Patient
12.3.2.10. Legg-Calve-Perthes Syndrome Patient
12.3.2.11. Mucopolysaccharidosis Patient
12.3.2.12. Neurofibromatosis Patient
12.3.2.13. Parkinson's Disease Patient
12.3.2.14. Psoriasis Patient
12.3.2.15. Rheumatoid Arthritis Patient
12.3.2.16. Systemic Lupus Erythematosus (SLE)
12.3.2.17. Transverse Myelitis Patient
12.3.2.18. Others
12.3.3. Serum-free Fibroblast Culture Medium
12.4. North America Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
12.4.1. Adults
12.4.2. Neonatal
12.5. North America Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Research and Academic Institutes
12.5.4. Others
12.6. North America Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
12.6.1.1.1. Human Dermal Fibroblasts
12.6.1.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
12.6.1.1.3. Others
12.6.1.2. U.S Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
12.6.1.2.1. Tissue Specific Fibroblasts
12.6.1.2.1.1. Skin
12.6.1.2.1.2. Mammary
12.6.1.2.1.3. Lung
12.6.1.2.1.4. Kidney
12.6.1.2.1.5. Muscle
12.6.1.2.1.6. Others
12.6.1.2.2. Disease-specific Fibroblasts
12.6.1.2.2.1. Astrocytoma
12.6.1.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
12.6.1.2.2.3. Wound Healing
12.6.1.2.2.4. Arteriovenous Malformation (AVM) Patient
12.6.1.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
12.6.1.2.2.6. Diabetes
12.6.1.2.2.7. Guillain-Barre Syndrome (GBS) Patient
12.6.1.2.2.8. Glioblastoma Patient
12.6.1.2.2.9. Huntington's Disease (HD) Patient
12.6.1.2.2.10. Legg-Calve-Perthes Syndrome Patient
12.6.1.2.2.11. Mucopolysaccharidosis Patient
12.6.1.2.2.12. Neurofibromatosis Patient
12.6.1.2.2.13. Parkinson's Disease Patient
12.6.1.2.2.14. Psoriasis Patient
12.6.1.2.2.15. Rheumatoid Arthritis Patient
12.6.1.2.2.16. Systemic Lupus Erythematosus (SLE)
12.6.1.2.2.17. Transverse Myelitis Patient
12.6.1.2.2.18. Others
12.6.1.2.3. Serum-free Fibroblast Culture Medium
12.6.1.3. U.S Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
12.6.1.3.1. Adults
12.6.1.3.2. Neonatal
12.6.1.4. U.S Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.1.4.1. Hospitals
12.6.1.4.2. Clinics
12.6.1.4.3. Research and Academic Institutes
12.6.1.4.4. Others
12.6.2. Canada
12.6.2.1. Canada Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
12.6.2.1.1. Human Dermal Fibroblasts
12.6.2.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
12.6.2.1.3. Others
12.6.2.2. Canada Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
12.6.2.2.1. Tissue Specific Fibroblasts
12.6.2.2.1.1. Skin
12.6.2.2.1.2. Mammary
12.6.2.2.1.3. Lung
12.6.2.2.1.4. Kidney
12.6.2.2.1.5. Muscle
12.6.2.2.1.6. Others
12.6.2.2.2. Disease-specific Fibroblasts
12.6.2.2.2.1. Astrocytoma
12.6.2.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
12.6.2.2.2.3. Wound Healing
12.6.2.2.2.4. Arteriovenous Malformation (AVM) Patient
12.6.2.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
12.6.2.2.2.6. Diabetes
12.6.2.2.2.7. Guillain-Barre Syndrome (GBS) Patient
12.6.2.2.2.8. Glioblastoma Patient
12.6.2.2.2.9. Huntington's Disease (HD) Patient
12.6.2.2.2.10. Legg-Calve-Perthes Syndrome Patient
12.6.2.2.2.11. Mucopolysaccharidosis Patient
12.6.2.2.2.12. Neurofibromatosis Patient
12.6.2.2.2.13. Parkinson's Disease Patient
12.6.2.2.2.14. Psoriasis Patient
12.6.2.2.2.15. Rheumatoid Arthritis Patient
12.6.2.2.2.16. Systemic Lupus Erythematosus (SLE)
12.6.2.2.2.17. Transverse Myelitis Patient
12.6.2.2.2.18. Others
12.6.2.2.3. Serum-free Fibroblast Culture Medium
12.6.2.3. Canada Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
12.6.2.3.1. Adults
12.6.2.3.2. Neonatal
12.6.2.4. Canada Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.2.4.1. Hospitals
12.6.2.4.2. Clinics
12.6.2.4.3. Research and Academic Institutes
12.6.2.4.4. Others
12.6.3. Mexico
12.6.3.1. Mexico Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
12.6.3.1.1. Human Dermal Fibroblasts
12.6.3.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
12.6.3.1.3. Others
12.6.3.2. Mexico Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
12.6.3.2.1. Tissue Specific Fibroblasts
12.6.3.2.1.1. Skin
12.6.3.2.1.2. Mammary
12.6.3.2.1.3. Lung
12.6.3.2.1.4. Kidney
12.6.3.2.1.5. Muscle
12.6.3.2.1.6. Others
12.6.3.2.2. Disease-specific Fibroblasts
12.6.3.2.2.1. Astrocytoma
12.6.3.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
12.6.3.2.2.3. Wound Healing
12.6.3.2.2.4. Arteriovenous Malformation (AVM) Patient
12.6.3.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
12.6.3.2.2.6. Diabetes
12.6.3.2.2.7. Guillain-Barre Syndrome (GBS) Patient
12.6.3.2.2.8. Glioblastoma Patient
12.6.3.2.2.9. Huntington's Disease (HD) Patient
12.6.3.2.2.10. Legg-Calve-Perthes Syndrome Patient
12.6.3.2.2.11. Mucopolysaccharidosis Patient
12.6.3.2.2.12. Neurofibromatosis Patient
12.6.3.2.2.13. Parkinson's Disease Patient
12.6.3.2.2.14. Psoriasis Patient
12.6.3.2.2.15. Rheumatoid Arthritis Patient
12.6.3.2.2.16. Systemic Lupus Erythematosus (SLE)
12.6.3.2.2.17. Transverse Myelitis Patient
12.6.3.2.2.18. Others
12.6.3.2.3. Serum-free Fibroblast Culture Medium
12.6.3.3. Mexico Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
12.6.3.3.1. Adults
12.6.3.3.2. Neonatal
12.6.3.4. Mexico Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.3.4.1. Hospitals
12.6.3.4.2. Clinics
12.6.3.4.3. Research and Academic Institutes
12.6.3.4.4. Others
12.6.4. Rest of North America
12.6.4.1. Rest of North America Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
12.6.4.1.1. Human Dermal Fibroblasts
12.6.4.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
12.6.4.1.3. Others
12.6.4.2. Rest of North America Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
12.6.4.2.1. Tissue Specific Fibroblasts
12.6.4.2.1.1. Skin
12.6.4.2.1.2. Mammary
12.6.4.2.1.3. Lung
12.6.4.2.1.4. Kidney
12.6.4.2.1.5. Muscle
12.6.4.2.1.6. Others
12.6.4.2.2. Disease-specific Fibroblasts
12.6.4.2.2.1. Astrocytoma
12.6.4.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
12.6.4.2.2.3. Wound Healing
12.6.4.2.2.4. Arteriovenous Malformation (AVM) Patient
12.6.4.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
12.6.4.2.2.6. Diabetes
12.6.4.2.2.7. Guillain-Barre Syndrome (GBS) Patient
12.6.4.2.2.8. Glioblastoma Patient
12.6.4.2.2.9. Huntington's Disease (HD) Patient
12.6.4.2.2.10. Legg-Calve-Perthes Syndrome Patient
12.6.4.2.2.11. Mucopolysaccharidosis Patient
12.6.4.2.2.12. Neurofibromatosis Patient
12.6.4.2.2.13. Parkinson's Disease Patient
12.6.4.2.2.14. Psoriasis Patient
12.6.4.2.2.15. Rheumatoid Arthritis Patient
12.6.4.2.2.16. Systemic Lupus Erythematosus (SLE)
12.6.4.2.2.17. Transverse Myelitis Patient
12.6.4.2.2.18. Others
12.6.4.2.3. Serum-free Fibroblast Culture Medium
12.6.4.3. Rest of North America Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
12.6.4.3.1. Adults
12.6.4.3.2. Neonatal
12.6.4.4. Rest of North America Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.4.4.1. Hospitals
12.6.4.4.2. Clinics
12.6.4.4.3. Research and Academic Institutes
12.6.4.4.4. Others
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Product Type
12.7.3. By Type
12.7.4. By Application
12.7.5. By End Users
13. Europe Fibroblast Cells Market Analysis and Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Europe Fibroblast Cells Market Revenue (US$ Mn)
13.2. Europe Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
13.2.1. Human Dermal Fibroblasts
13.2.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
13.2.3. Others
13.3. Europe Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
13.3.1. Tissue Specific Fibroblasts
13.3.1.1. Skin
13.3.1.2. Mammary
13.3.1.3. Lung
13.3.1.4. Kidney
13.3.1.5. Muscle
13.3.1.6. Others
13.3.2. Disease-specific Fibroblasts
13.3.2.1. Astrocytoma
13.3.2.2. Amyotrophic Lateral Sclerosis (ALS)
13.3.2.3. Wound Healing
13.3.2.4. Arteriovenous Malformation (AVM) Patient
13.3.2.5. Duchenne Muscular Dystrophy (DMD) Patient
13.3.2.6. Diabetes
13.3.2.7. Guillain-Barre Syndrome (GBS) Patient
13.3.2.8. Glioblastoma Patient
13.3.2.9. Huntington's Disease (HD) Patient
13.3.2.10. Legg-Calve-Perthes Syndrome Patient
13.3.2.11. Mucopolysaccharidosis Patient
13.3.2.12. Neurofibromatosis Patient
13.3.2.13. Parkinson's Disease Patient
13.3.2.14. Psoriasis Patient
13.3.2.15. Rheumatoid Arthritis Patient
13.3.2.16. Systemic Lupus Erythematosus (SLE)
13.3.2.17. Transverse Myelitis Patient
13.3.2.18. Others
13.3.3. Serum-free Fibroblast Culture Medium
13.4. Europe Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
13.4.1. Adults
13.4.2. Neonatal
13.5. Europe Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Research and Academic Institutes
13.5.4. Others
13.6. Europe Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
13.6.1.1.1. Human Dermal Fibroblasts
13.6.1.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
13.6.1.1.3. Others
13.6.1.2. France Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
13.6.1.2.1. Tissue Specific Fibroblasts
13.6.1.2.1.1. Skin
13.6.1.2.1.2. Mammary
13.6.1.2.1.3. Lung
13.6.1.2.1.4. Kidney
13.6.1.2.1.5. Muscle
13.6.1.2.1.6. Others
13.6.1.2.2. Disease-specific Fibroblasts
13.6.1.2.2.1. Astrocytoma
13.6.1.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
13.6.1.2.2.3. Wound Healing
13.6.1.2.2.4. Arteriovenous Malformation (AVM) Patient
13.6.1.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
13.6.1.2.2.6. Diabetes
13.6.1.2.2.7. Guillain-Barre Syndrome (GBS) Patient
13.6.1.2.2.8. Glioblastoma Patient
13.6.1.2.2.9. Huntington's Disease (HD) Patient
13.6.1.2.2.10. Legg-Calve-Perthes Syndrome Patient
13.6.1.2.2.11. Mucopolysaccharidosis Patient
13.6.1.2.2.12. Neurofibromatosis Patient
13.6.1.2.2.13. Parkinson's Disease Patient
13.6.1.2.2.14. Psoriasis Patient
13.6.1.2.2.15. Rheumatoid Arthritis Patient
13.6.1.2.2.16. Systemic Lupus Erythematosus (SLE)
13.6.1.2.2.17. Transverse Myelitis Patient
13.6.1.2.2.18. Others
13.6.1.2.3. Serum-free Fibroblast Culture Medium
13.6.1.3. France Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
13.6.1.3.1. Adults
13.6.1.3.2. Neonatal
13.6.1.4. France Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.1.4.1. Hospitals
13.6.1.4.2. Clinics
13.6.1.4.3. Research and Academic Institutes
13.6.1.4.4. Others
13.6.2. The UK
13.6.2.1. The UK Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
13.6.2.1.1. Human Dermal Fibroblasts
13.6.2.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
13.6.2.1.3. Others
13.6.2.2. The UK Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
13.6.2.2.1. Tissue Specific Fibroblasts
13.6.2.2.1.1. Skin
13.6.2.2.1.2. Mammary
13.6.2.2.1.3. Lung
13.6.2.2.1.4. Kidney
13.6.2.2.1.5. Muscle
13.6.2.2.1.6. Others
13.6.2.2.2. Disease-specific Fibroblasts
13.6.2.2.2.1. Astrocytoma
13.6.2.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
13.6.2.2.2.3. Wound Healing
13.6.2.2.2.4. Arteriovenous Malformation (AVM) Patient
13.6.2.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
13.6.2.2.2.6. Diabetes
13.6.2.2.2.7. Guillain-Barre Syndrome (GBS) Patient
13.6.2.2.2.8. Glioblastoma Patient
13.6.2.2.2.9. Huntington's Disease (HD) Patient
13.6.2.2.2.10. Legg-Calve-Perthes Syndrome Patient
13.6.2.2.2.11. Mucopolysaccharidosis Patient
13.6.2.2.2.12. Neurofibromatosis Patient
13.6.2.2.2.13. Parkinson's Disease Patient
13.6.2.2.2.14. Psoriasis Patient
13.6.2.2.2.15. Rheumatoid Arthritis Patient
13.6.2.2.2.16. Systemic Lupus Erythematosus (SLE)
13.6.2.2.2.17. Transverse Myelitis Patient
13.6.2.2.2.18. Others
13.6.2.2.3. Serum-free Fibroblast Culture Medium
13.6.2.3. The UK Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
13.6.2.3.1. Adults
13.6.2.3.2. Neonatal
13.6.2.4. The UK Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.2.4.1. Hospitals
13.6.2.4.2. Clinics
13.6.2.4.3. Research and Academic Institutes
13.6.2.4.4. Others
13.6.3. Spain
13.6.3.1. Spain Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
13.6.3.1.1. Human Dermal Fibroblasts
13.6.3.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
13.6.3.1.3. Others
13.6.3.2. Spain Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
13.6.3.2.1. Tissue Specific Fibroblasts
13.6.3.2.1.1. Skin
13.6.3.2.1.2. Mammary
13.6.3.2.1.3. Lung
13.6.3.2.1.4. Kidney
13.6.3.2.1.5. Muscle
13.6.3.2.1.6. Others
13.6.3.2.2. Disease-specific Fibroblasts
13.6.3.2.2.1. Astrocytoma
13.6.3.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
13.6.3.2.2.3. Wound Healing
13.6.3.2.2.4. Arteriovenous Malformation (AVM) Patient
13.6.3.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
13.6.3.2.2.6. Diabetes
13.6.3.2.2.7. Guillain-Barre Syndrome (GBS) Patient
13.6.3.2.2.8. Glioblastoma Patient
13.6.3.2.2.9. Huntington's Disease (HD) Patient
13.6.3.2.2.10. Legg-Calve-Perthes Syndrome Patient
13.6.3.2.2.11. Mucopolysaccharidosis Patient
13.6.3.2.2.12. Neurofibromatosis Patient
13.6.3.2.2.13. Parkinson's Disease Patient
13.6.3.2.2.14. Psoriasis Patient
13.6.3.2.2.15. Rheumatoid Arthritis Patient
13.6.3.2.2.16. Systemic Lupus Erythematosus (SLE)
13.6.3.2.2.17. Transverse Myelitis Patient
13.6.3.2.2.18. Others
13.6.3.2.3. Serum-free Fibroblast Culture Medium
13.6.3.3. Spain Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
13.6.3.3.1. Adults
13.6.3.3.2. Neonatal
13.6.3.4. Spain Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.3.4.1. Hospitals
13.6.3.4.2. Clinics
13.6.3.4.3. Research and Academic Institutes
13.6.3.4.4. Others
13.6.4. Germany
13.6.4.1. Germany Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
13.6.4.1.1. Human Dermal Fibroblasts
13.6.4.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
13.6.4.1.3. Others
13.6.4.2. Germany Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
13.6.4.2.1. Tissue Specific Fibroblasts
13.6.4.2.1.1. Skin
13.6.4.2.1.2. Mammary
13.6.4.2.1.3. Lung
13.6.4.2.1.4. Kidney
13.6.4.2.1.5. Muscle
13.6.4.2.1.6. Others
13.6.4.2.2. Disease-specific Fibroblasts
13.6.4.2.2.1. Astrocytoma
13.6.4.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
13.6.4.2.2.3. Wound Healing
13.6.4.2.2.4. Arteriovenous Malformation (AVM) Patient
13.6.4.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
13.6.4.2.2.6. Diabetes
13.6.4.2.2.7. Guillain-Barre Syndrome (GBS) Patient
13.6.4.2.2.8. Glioblastoma Patient
13.6.4.2.2.9. Huntington's Disease (HD) Patient
13.6.4.2.2.10. Legg-Calve-Perthes Syndrome Patient
13.6.4.2.2.11. Mucopolysaccharidosis Patient
13.6.4.2.2.12. Neurofibromatosis Patient
13.6.4.2.2.13. Parkinson's Disease Patient
13.6.4.2.2.14. Psoriasis Patient
13.6.4.2.2.15. Rheumatoid Arthritis Patient
13.6.4.2.2.16. Systemic Lupus Erythematosus (SLE)
13.6.4.2.2.17. Transverse Myelitis Patient
13.6.4.2.2.18. Others
13.6.4.2.3. Serum-free Fibroblast Culture Medium
13.6.4.3. Germany Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
13.6.4.3.1. Adults
13.6.4.3.2. Neonatal
13.6.4.4. Germany Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.4.4.1. Hospitals
13.6.4.4.2. Clinics
13.6.4.4.3. Research and Academic Institutes
13.6.4.4.4. Others
13.6.5. Italy
13.6.5.1. Italy Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
13.6.5.1.1. Human Dermal Fibroblasts
13.6.5.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
13.6.5.1.3. Others
13.6.5.2. Italy Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
13.6.5.2.1. Tissue Specific Fibroblasts
13.6.5.2.1.1. Skin
13.6.5.2.1.2. Mammary
13.6.5.2.1.3. Lung
13.6.5.2.1.4. Kidney
13.6.5.2.1.5. Muscle
13.6.5.2.1.6. Others
13.6.5.2.2. Disease-specific Fibroblasts
13.6.5.2.2.1. Astrocytoma
13.6.5.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
13.6.5.2.2.3. Wound Healing
13.6.5.2.2.4. Arteriovenous Malformation (AVM) Patient
13.6.5.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
13.6.5.2.2.6. Diabetes
13.6.5.2.2.7. Guillain-Barre Syndrome (GBS) Patient
13.6.5.2.2.8. Glioblastoma Patient
13.6.5.2.2.9. Huntington's Disease (HD) Patient
13.6.5.2.2.10. Legg-Calve-Perthes Syndrome Patient
13.6.5.2.2.11. Mucopolysaccharidosis Patient
13.6.5.2.2.12. Neurofibromatosis Patient
13.6.5.2.2.13. Parkinson's Disease Patient
13.6.5.2.2.14. Psoriasis Patient
13.6.5.2.2.15. Rheumatoid Arthritis Patient
13.6.5.2.2.16. Systemic Lupus Erythematosus (SLE)
13.6.5.2.2.17. Transverse Myelitis Patient
13.6.5.2.2.18. Others
13.6.5.2.3. Serum-free Fibroblast Culture Medium
13.6.5.3. Italy Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
13.6.5.3.1. Adults
13.6.5.3.2. Neonatal
13.6.5.4. Italy Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.5.4.1. Hospitals
13.6.5.4.2. Clinics
13.6.5.4.3. Research and Academic Institutes
13.6.5.4.4. Others
13.6.6. Nordic Countries
13.6.6.1. Nordic Countries Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
13.6.6.1.1. Human Dermal Fibroblasts
13.6.6.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
13.6.6.1.3. Others
13.6.6.2. Nordic Countries Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
13.6.6.2.1. Tissue Specific Fibroblasts
13.6.6.2.1.1. Skin
13.6.6.2.1.2. Mammary
13.6.6.2.1.3. Lung
13.6.6.2.1.4. Kidney
13.6.6.2.1.5. Muscle
13.6.6.2.1.6. Others
13.6.6.2.2. Disease-specific Fibroblasts
13.6.6.2.2.1. Astrocytoma
13.6.6.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
13.6.6.2.2.3. Wound Healing
13.6.6.2.2.4. Arteriovenous Malformation (AVM) Patient
13.6.6.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
13.6.6.2.2.6. Diabetes
13.6.6.2.2.7. Guillain-Barre Syndrome (GBS) Patient
13.6.6.2.2.8. Glioblastoma Patient
13.6.6.2.2.9. Huntington's Disease (HD) Patient
13.6.6.2.2.10. Legg-Calve-Perthes Syndrome Patient
13.6.6.2.2.11. Mucopolysaccharidosis Patient
13.6.6.2.2.12. Neurofibromatosis Patient
13.6.6.2.2.13. Parkinson's Disease Patient
13.6.6.2.2.14. Psoriasis Patient
13.6.6.2.2.15. Rheumatoid Arthritis Patient
13.6.6.2.2.16. Systemic Lupus Erythematosus (SLE)
13.6.6.2.2.17. Transverse Myelitis Patient
13.6.6.2.2.18. Others
13.6.6.2.3. Serum-free Fibroblast Culture Medium
13.6.6.3. Nordic Countries Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
13.6.6.3.1. Adults
13.6.6.3.2. Neonatal
13.6.6.4. Nordic Countries Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.6.4.1. Hospitals
13.6.6.4.2. Clinics
13.6.6.4.3. Research and Academic Institutes
13.6.6.4.4. Others
13.6.6.5. Nordic Countries Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux Union
13.6.7.1. Benelux Union Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
13.6.7.1.1. Human Dermal Fibroblasts
13.6.7.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
13.6.7.1.3. Others
13.6.7.2. Benelux Union Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
13.6.7.2.1. Tissue Specific Fibroblasts
13.6.7.2.1.1. Skin
13.6.7.2.1.2. Mammary
13.6.7.2.1.3. Lung
13.6.7.2.1.4. Kidney
13.6.7.2.1.5. Muscle
13.6.7.2.1.6. Others
13.6.7.2.2. Disease-specific Fibroblasts
13.6.7.2.2.1. Astrocytoma
13.6.7.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
13.6.7.2.2.3. Wound Healing
13.6.7.2.2.4. Arteriovenous Malformation (AVM) Patient
13.6.7.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
13.6.7.2.2.6. Diabetes
13.6.7.2.2.7. Guillain-Barre Syndrome (GBS) Patient
13.6.7.2.2.8. Glioblastoma Patient
13.6.7.2.2.9. Huntington's Disease (HD) Patient
13.6.7.2.2.10. Legg-Calve-Perthes Syndrome Patient
13.6.7.2.2.11. Mucopolysaccharidosis Patient
13.6.7.2.2.12. Neurofibromatosis Patient
13.6.7.2.2.13. Parkinson's Disease Patient
13.6.7.2.2.14. Psoriasis Patient
13.6.7.2.2.15. Rheumatoid Arthritis Patient
13.6.7.2.2.16. Systemic Lupus Erythematosus (SLE)
13.6.7.2.2.17. Transverse Myelitis Patient
13.6.7.2.2.18. Others
13.6.7.2.3. Serum-free Fibroblast Culture Medium
13.6.7.3. Benelux Union Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
13.6.7.3.1. Adults
13.6.7.3.2. Neonatal
13.6.7.4. Benelux Union Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.7.4.1. Hospitals
13.6.7.4.2. Clinics
13.6.7.4.3. Research and Academic Institutes
13.6.7.4.4. Others
13.6.7.5. Benelux Union Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of Europe
13.6.8.1. Rest of Europe Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
13.6.8.1.1. Human Dermal Fibroblasts
13.6.8.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
13.6.8.1.3. Others
13.6.8.2. Rest of Europe Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
13.6.8.2.1. Tissue Specific Fibroblasts
13.6.8.2.1.1. Skin
13.6.8.2.1.2. Mammary
13.6.8.2.1.3. Lung
13.6.8.2.1.4. Kidney
13.6.8.2.1.5. Muscle
13.6.8.2.1.6. Others
13.6.8.2.2. Disease-specific Fibroblasts
13.6.8.2.2.1. Astrocytoma
13.6.8.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
13.6.8.2.2.3. Wound Healing
13.6.8.2.2.4. Arteriovenous Malformation (AVM) Patient
13.6.8.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
13.6.8.2.2.6. Diabetes
13.6.8.2.2.7. Guillain-Barre Syndrome (GBS) Patient
13.6.8.2.2.8. Glioblastoma Patient
13.6.8.2.2.9. Huntington's Disease (HD) Patient
13.6.8.2.2.10. Legg-Calve-Perthes Syndrome Patient
13.6.8.2.2.11. Mucopolysaccharidosis Patient
13.6.8.2.2.12. Neurofibromatosis Patient
13.6.8.2.2.13. Parkinson's Disease Patient
13.6.8.2.2.14. Psoriasis Patient
13.6.8.2.2.15. Rheumatoid Arthritis Patient
13.6.8.2.2.16. Systemic Lupus Erythematosus (SLE)
13.6.8.2.2.17. Transverse Myelitis Patient
13.6.8.2.2.18. Others
13.6.8.2.3. Serum-free Fibroblast Culture Medium
13.6.8.3. Rest of Europe Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
13.6.8.3.1. Adults
13.6.8.3.2. Neonatal
13.6.8.4. Rest of Europe Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.8.4.1. Hospitals
13.6.8.4.2. Clinics
13.6.8.4.3. Research and Academic Institutes
13.6.8.4.4. Others
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Product Type
13.7.3. By Type
13.7.4. By Application
13.7.5. By End Users
14. Asia Pacific Fibroblast Cells Market Analysis and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Asia Pacific Fibroblast Cells Market Revenue (US$ Mn)
14.2. Asia Pacific Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
14.2.1. Human Dermal Fibroblasts
14.2.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
14.2.3. Others
14.3. Asia Pacific Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
14.3.1. Tissue Specific Fibroblasts
14.3.1.1. Skin
14.3.1.2. Mammary
14.3.1.3. Lung
14.3.1.4. Kidney
14.3.1.5. Muscle
14.3.1.6. Others
14.3.2. Disease-specific Fibroblasts
14.3.2.1. Astrocytoma
14.3.2.2. Amyotrophic Lateral Sclerosis (ALS)
14.3.2.3. Wound Healing
14.3.2.4. Arteriovenous Malformation (AVM) Patient
14.3.2.5. Duchenne Muscular Dystrophy (DMD) Patient
14.3.2.6. Diabetes
14.3.2.7. Guillain-Barre Syndrome (GBS) Patient
14.3.2.8. Glioblastoma Patient
14.3.2.9. Huntington's Disease (HD) Patient
14.3.2.10. Legg-Calve-Perthes Syndrome Patient
14.3.2.11. Mucopolysaccharidosis Patient
14.3.2.12. Neurofibromatosis Patient
14.3.2.13. Parkinson's Disease Patient
14.3.2.14. Psoriasis Patient
14.3.2.15. Rheumatoid Arthritis Patient
14.3.2.16. Systemic Lupus Erythematosus (SLE)
14.3.2.17. Transverse Myelitis Patient
14.3.2.18. Others
14.3.3. Serum-free Fibroblast Culture Medium
14.4. Asia Pacific Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
14.4.1. Adults
14.4.2. Neonatal
14.5. Asia Pacific Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Research and Academic Institutes
14.5.4. Others
14.6. Asia Pacific Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1. China Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
14.6.1.1.1. Human Dermal Fibroblasts
14.6.1.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
14.6.1.1.3. Others
14.6.1.2. China Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
14.6.1.2.1. Tissue Specific Fibroblasts
14.6.1.2.1.1. Skin
14.6.1.2.1.2. Mammary
14.6.1.2.1.3. Lung
14.6.1.2.1.4. Kidney
14.6.1.2.1.5. Muscle
14.6.1.2.1.6. Others
14.6.1.2.2. Disease-specific Fibroblasts
14.6.1.2.2.1. Astrocytoma
14.6.1.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
14.6.1.2.2.3. Wound Healing
14.6.1.2.2.4. Arteriovenous Malformation (AVM) Patient
14.6.1.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
14.6.1.2.2.6. Diabetes
14.6.1.2.2.7. Guillain-Barre Syndrome (GBS) Patient
14.6.1.2.2.8. Glioblastoma Patient
14.6.1.2.2.9. Huntington's Disease (HD) Patient
14.6.1.2.2.10. Legg-Calve-Perthes Syndrome Patient
14.6.1.2.2.11. Mucopolysaccharidosis Patient
14.6.1.2.2.12. Neurofibromatosis Patient
14.6.1.2.2.13. Parkinson's Disease Patient
14.6.1.2.2.14. Psoriasis Patient
14.6.1.2.2.15. Rheumatoid Arthritis Patient
14.6.1.2.2.16. Systemic Lupus Erythematosus (SLE)
14.6.1.2.2.17. Transverse Myelitis Patient
14.6.1.2.2.18. Others
14.6.1.2.3. Serum-free Fibroblast Culture Medium
14.6.1.3. China Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
14.6.1.3.1. Adults
14.6.1.3.2. Neonatal
14.6.1.4. China Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.1.4.1. Hospitals
14.6.1.4.2. Clinics
14.6.1.4.3. Research and Academic Institutes
14.6.1.4.4. Others
14.6.2. Japan
14.6.2.1. Japan Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
14.6.2.1.1. Human Dermal Fibroblasts
14.6.2.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
14.6.2.1.3. Others
14.6.2.2. Japan Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
14.6.2.2.1. Tissue Specific Fibroblasts
14.6.2.2.1.1. Skin
14.6.2.2.1.2. Mammary
14.6.2.2.1.3. Lung
14.6.2.2.1.4. Kidney
14.6.2.2.1.5. Muscle
14.6.2.2.1.6. Others
14.6.2.2.2. Disease-specific Fibroblasts
14.6.2.2.2.1. Astrocytoma
14.6.2.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
14.6.2.2.2.3. Wound Healing
14.6.2.2.2.4. Arteriovenous Malformation (AVM) Patient
14.6.2.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
14.6.2.2.2.6. Diabetes
14.6.2.2.2.7. Guillain-Barre Syndrome (GBS) Patient
14.6.2.2.2.8. Glioblastoma Patient
14.6.2.2.2.9. Huntington's Disease (HD) Patient
14.6.2.2.2.10. Legg-Calve-Perthes Syndrome Patient
14.6.2.2.2.11. Mucopolysaccharidosis Patient
14.6.2.2.2.12. Neurofibromatosis Patient
14.6.2.2.2.13. Parkinson's Disease Patient
14.6.2.2.2.14. Psoriasis Patient
14.6.2.2.2.15. Rheumatoid Arthritis Patient
14.6.2.2.2.16. Systemic Lupus Erythematosus (SLE)
14.6.2.2.2.17. Transverse Myelitis Patient
14.6.2.2.2.18. Others
14.6.2.2.3. Serum-free Fibroblast Culture Medium
14.6.2.3. Japan Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
14.6.2.3.1. Adults
14.6.2.3.2. Neonatal
14.6.2.4. Japan Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.2.4.1. Hospitals
14.6.2.4.2. Clinics
14.6.2.4.3. Research and Academic Institutes
14.6.2.4.4. Others
14.6.3. India
14.6.3.1. India Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
14.6.3.1.1. Human Dermal Fibroblasts
14.6.3.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
14.6.3.1.3. Others
14.6.3.2. India Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
14.6.3.2.1. Tissue Specific Fibroblasts
14.6.3.2.1.1. Skin
14.6.3.2.1.2. Mammary
14.6.3.2.1.3. Lung
14.6.3.2.1.4. Kidney
14.6.3.2.1.5. Muscle
14.6.3.2.1.6. Others
14.6.3.2.2. Disease-specific Fibroblasts
14.6.3.2.2.1. Astrocytoma
14.6.3.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
14.6.3.2.2.3. Wound Healing
14.6.3.2.2.4. Arteriovenous Malformation (AVM) Patient
14.6.3.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
14.6.3.2.2.6. Diabetes
14.6.3.2.2.7. Guillain-Barre Syndrome (GBS) Patient
14.6.3.2.2.8. Glioblastoma Patient
14.6.3.2.2.9. Huntington's Disease (HD) Patient
14.6.3.2.2.10. Legg-Calve-Perthes Syndrome Patient
14.6.3.2.2.11. Mucopolysaccharidosis Patient
14.6.3.2.2.12. Neurofibromatosis Patient
14.6.3.2.2.13. Parkinson's Disease Patient
14.6.3.2.2.14. Psoriasis Patient
14.6.3.2.2.15. Rheumatoid Arthritis Patient
14.6.3.2.2.16. Systemic Lupus Erythematosus (SLE)
14.6.3.2.2.17. Transverse Myelitis Patient
14.6.3.2.2.18. Others
14.6.3.2.3. Serum-free Fibroblast Culture Medium
14.6.3.3. India Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
14.6.3.3.1. Adults
14.6.3.3.2. Neonatal
14.6.3.4. India Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.3.4.1. Hospitals
14.6.3.4.2. Clinics
14.6.3.4.3. Research and Academic Institutes
14.6.3.4.4. Others
14.6.4. New Zealand
14.6.4.1. New Zealand Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
14.6.4.1.1. Human Dermal Fibroblasts
14.6.4.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
14.6.4.1.3. Others
14.6.4.2. New Zealand Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
14.6.4.2.1. Tissue Specific Fibroblasts
14.6.4.2.1.1. Skin
14.6.4.2.1.2. Mammary
14.6.4.2.1.3. Lung
14.6.4.2.1.4. Kidney
14.6.4.2.1.5. Muscle
14.6.4.2.1.6. Others
14.6.4.2.2. Disease-specific Fibroblasts
14.6.4.2.2.1. Astrocytoma
14.6.4.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
14.6.4.2.2.3. Wound Healing
14.6.4.2.2.4. Arteriovenous Malformation (AVM) Patient
14.6.4.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
14.6.4.2.2.6. Diabetes
14.6.4.2.2.7. Guillain-Barre Syndrome (GBS) Patient
14.6.4.2.2.8. Glioblastoma Patient
14.6.4.2.2.9. Huntington's Disease (HD) Patient
14.6.4.2.2.10. Legg-Calve-Perthes Syndrome Patient
14.6.4.2.2.11. Mucopolysaccharidosis Patient
14.6.4.2.2.12. Neurofibromatosis Patient
14.6.4.2.2.13. Parkinson's Disease Patient
14.6.4.2.2.14. Psoriasis Patient
14.6.4.2.2.15. Rheumatoid Arthritis Patient
14.6.4.2.2.16. Systemic Lupus Erythematosus (SLE)
14.6.4.2.2.17. Transverse Myelitis Patient
14.6.4.2.2.18. Others
14.6.4.2.3. Serum-free Fibroblast Culture Medium
14.6.4.3. New Zealand Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
14.6.4.3.1. Adults
14.6.4.3.2. Neonatal
14.6.4.4. New Zealand Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.4.4.1. Hospitals
14.6.4.4.2. Clinics
14.6.4.4.3. Research and Academic Institutes
14.6.4.4.4. Others
14.6.5. Australia
14.6.5.1. Australia Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
14.6.5.1.1. Human Dermal Fibroblasts
14.6.5.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
14.6.5.1.3. Others
14.6.5.2. Australia Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
14.6.5.2.1. Tissue Specific Fibroblasts
14.6.5.2.1.1. Skin
14.6.5.2.1.2. Mammary
14.6.5.2.1.3. Lung
14.6.5.2.1.4. Kidney
14.6.5.2.1.5. Muscle
14.6.5.2.1.6. Others
14.6.5.2.2. Disease-specific Fibroblasts
14.6.5.2.2.1. Astrocytoma
14.6.5.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
14.6.5.2.2.3. Wound Healing
14.6.5.2.2.4. Arteriovenous Malformation (AVM) Patient
14.6.5.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
14.6.5.2.2.6. Diabetes
14.6.5.2.2.7. Guillain-Barre Syndrome (GBS) Patient
14.6.5.2.2.8. Glioblastoma Patient
14.6.5.2.2.9. Huntington's Disease (HD) Patient
14.6.5.2.2.10. Legg-Calve-Perthes Syndrome Patient
14.6.5.2.2.11. Mucopolysaccharidosis Patient
14.6.5.2.2.12. Neurofibromatosis Patient
14.6.5.2.2.13. Parkinson's Disease Patient
14.6.5.2.2.14. Psoriasis Patient
14.6.5.2.2.15. Rheumatoid Arthritis Patient
14.6.5.2.2.16. Systemic Lupus Erythematosus (SLE)
14.6.5.2.2.17. Transverse Myelitis Patient
14.6.5.2.2.18. Others
14.6.5.2.3. Serum-free Fibroblast Culture Medium
14.6.5.3. Australia Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
14.6.5.3.1. Adults
14.6.5.3.2. Neonatal
14.6.5.4. Australia Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.5.4.1. Hospitals
14.6.5.4.2. Clinics
14.6.5.4.3. Research and Academic Institutes
14.6.5.4.4. Others
14.6.6. South Korea
14.6.6.1. South Korea Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
14.6.6.1.1. Human Dermal Fibroblasts
14.6.6.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
14.6.6.1.3. Others
14.6.6.2. South Korea Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
14.6.6.2.1. Tissue Specific Fibroblasts
14.6.6.2.1.1. Skin
14.6.6.2.1.2. Mammary
14.6.6.2.1.3. Lung
14.6.6.2.1.4. Kidney
14.6.6.2.1.5. Muscle
14.6.6.2.1.6. Others
14.6.6.2.2. Disease-specific Fibroblasts
14.6.6.2.2.1. Astrocytoma
14.6.6.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
14.6.6.2.2.3. Wound Healing
14.6.6.2.2.4. Arteriovenous Malformation (AVM) Patient
14.6.6.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
14.6.6.2.2.6. Diabetes
14.6.6.2.2.7. Guillain-Barre Syndrome (GBS) Patient
14.6.6.2.2.8. Glioblastoma Patient
14.6.6.2.2.9. Huntington's Disease (HD) Patient
14.6.6.2.2.10. Legg-Calve-Perthes Syndrome Patient
14.6.6.2.2.11. Mucopolysaccharidosis Patient
14.6.6.2.2.12. Neurofibromatosis Patient
14.6.6.2.2.13. Parkinson's Disease Patient
14.6.6.2.2.14. Psoriasis Patient
14.6.6.2.2.15. Rheumatoid Arthritis Patient
14.6.6.2.2.16. Systemic Lupus Erythematosus (SLE)
14.6.6.2.2.17. Transverse Myelitis Patient
14.6.6.2.2.18. Others
14.6.6.2.3. Serum-free Fibroblast Culture Medium
14.6.6.3. South Korea Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
14.6.6.3.1. Adults
14.6.6.3.2. Neonatal
14.6.6.4. South Korea Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.6.4.1. Hospitals
14.6.6.4.2. Clinics
14.6.6.4.3. Research and Academic Institutes
14.6.6.4.4. Others
14.6.7. Southeast Asia
14.6.7.1. Southeast Asia Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
14.6.7.1.1. Human Dermal Fibroblasts
14.6.7.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
14.6.7.1.3. Others
14.6.7.2. Southeast Asia Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
14.6.7.2.1. Tissue Specific Fibroblasts
14.6.7.2.1.1. Skin
14.6.7.2.1.2. Mammary
14.6.7.2.1.3. Lung
14.6.7.2.1.4. Kidney
14.6.7.2.1.5. Muscle
14.6.7.2.1.6. Others
14.6.7.2.2. Disease-specific Fibroblasts
14.6.7.2.2.1. Astrocytoma
14.6.7.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
14.6.7.2.2.3. Wound Healing
14.6.7.2.2.4. Arteriovenous Malformation (AVM) Patient
14.6.7.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
14.6.7.2.2.6. Diabetes
14.6.7.2.2.7. Guillain-Barre Syndrome (GBS) Patient
14.6.7.2.2.8. Glioblastoma Patient
14.6.7.2.2.9. Huntington's Disease (HD) Patient
14.6.7.2.2.10. Legg-Calve-Perthes Syndrome Patient
14.6.7.2.2.11. Mucopolysaccharidosis Patient
14.6.7.2.2.12. Neurofibromatosis Patient
14.6.7.2.2.13. Parkinson's Disease Patient
14.6.7.2.2.14. Psoriasis Patient
14.6.7.2.2.15. Rheumatoid Arthritis Patient
14.6.7.2.2.16. Systemic Lupus Erythematosus (SLE)
14.6.7.2.2.17. Transverse Myelitis Patient
14.6.7.2.2.18. Others
14.6.7.2.3. Serum-free Fibroblast Culture Medium
14.6.7.3. Southeast Asia Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
14.6.7.3.1. Adults
14.6.7.3.2. Neonatal
14.6.7.4. Southeast Asia Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.7.4.1. Hospitals
14.6.7.4.2. Clinics
14.6.7.4.3. Research and Academic Institutes
14.6.7.4.4. Others
14.6.7.5. Southeast Asia Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1. Rest of Asia Pacific Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
14.6.8.1.1. Human Dermal Fibroblasts
14.6.8.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
14.6.8.1.3. Others
14.6.8.2. Rest of Asia Pacific Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
14.6.8.2.1. Tissue Specific Fibroblasts
14.6.8.2.1.1. Skin
14.6.8.2.1.2. Mammary
14.6.8.2.1.3. Lung
14.6.8.2.1.4. Kidney
14.6.8.2.1.5. Muscle
14.6.8.2.1.6. Others
14.6.8.2.2. Disease-specific Fibroblasts
14.6.8.2.2.1. Astrocytoma
14.6.8.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
14.6.8.2.2.3. Wound Healing
14.6.8.2.2.4. Arteriovenous Malformation (AVM) Patient
14.6.8.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
14.6.8.2.2.6. Diabetes
14.6.8.2.2.7. Guillain-Barre Syndrome (GBS) Patient
14.6.8.2.2.8. Glioblastoma Patient
14.6.8.2.2.9. Huntington's Disease (HD) Patient
14.6.8.2.2.10. Legg-Calve-Perthes Syndrome Patient
14.6.8.2.2.11. Mucopolysaccharidosis Patient
14.6.8.2.2.12. Neurofibromatosis Patient
14.6.8.2.2.13. Parkinson's Disease Patient
14.6.8.2.2.14. Psoriasis Patient
14.6.8.2.2.15. Rheumatoid Arthritis Patient
14.6.8.2.2.16. Systemic Lupus Erythematosus (SLE)
14.6.8.2.2.17. Transverse Myelitis Patient
14.6.8.2.2.18. Others
14.6.8.2.3. Serum-free Fibroblast Culture Medium
14.6.8.3. Rest of Asia Pacific Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
14.6.8.3.1. Adults
14.6.8.3.2. Neonatal
14.6.8.4. Rest of Asia Pacific Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.8.4.1. Hospitals
14.6.8.4.2. Clinics
14.6.8.4.3. Research and Academic Institutes
14.6.8.4.4. Others
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Product Type
14.7.3. By Type
14.7.4. By Application
14.7.5. By End Users
15. Middle East and Africa Fibroblast Cells Market Analysis and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Middle East and Africa Fibroblast Cells Market Revenue (US$ Mn)
15.2. Middle East and Africa Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
15.2.1. Human Dermal Fibroblasts
15.2.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
15.2.3. Others
15.3. Middle East and Africa Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
15.3.1. Tissue Specific Fibroblasts
15.3.1.1. Skin
15.3.1.2. Mammary
15.3.1.3. Lung
15.3.1.4. Kidney
15.3.1.5. Muscle
15.3.1.6. Others
15.3.2. Disease-specific Fibroblasts
15.3.2.1. Astrocytoma
15.3.2.2. Amyotrophic Lateral Sclerosis (ALS)
15.3.2.3. Wound Healing
15.3.2.4. Arteriovenous Malformation (AVM) Patient
15.3.2.5. Duchenne Muscular Dystrophy (DMD) Patient
15.3.2.6. Diabetes
15.3.2.7. Guillain-Barre Syndrome (GBS) Patient
15.3.2.8. Glioblastoma Patient
15.3.2.9. Huntington's Disease (HD) Patient
15.3.2.10. Legg-Calve-Perthes Syndrome Patient
15.3.2.11. Mucopolysaccharidosis Patient
15.3.2.12. Neurofibromatosis Patient
15.3.2.13. Parkinson's Disease Patient
15.3.2.14. Psoriasis Patient
15.3.2.15. Rheumatoid Arthritis Patient
15.3.2.16. Systemic Lupus Erythematosus (SLE)
15.3.2.17. Transverse Myelitis Patient
15.3.2.18. Others
15.3.3. Serum-free Fibroblast Culture Medium
15.4. Middle East and Africa Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
15.4.1. Adults
15.4.2. Neonatal
15.5. Middle East and Africa Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
15.5.1. Hospitals
15.5.2. Clinics
15.5.3. Research and Academic Institutes
15.5.4. Others
15.6. Middle East and Africa Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1. Saudi Arabia Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
15.6.1.1.1. Human Dermal Fibroblasts
15.6.1.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
15.6.1.1.3. Others
15.6.1.2. Saudi Arabia Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
15.6.1.2.1. Tissue Specific Fibroblasts
15.6.1.2.1.1. Skin
15.6.1.2.1.2. Mammary
15.6.1.2.1.3. Lung
15.6.1.2.1.4. Kidney
15.6.1.2.1.5. Muscle
15.6.1.2.1.6. Others
15.6.1.2.2. Disease-specific Fibroblasts
15.6.1.2.2.1. Astrocytoma
15.6.1.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
15.6.1.2.2.3. Wound Healing
15.6.1.2.2.4. Arteriovenous Malformation (AVM) Patient
15.6.1.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
15.6.1.2.2.6. Diabetes
15.6.1.2.2.7. Guillain-Barre Syndrome (GBS) Patient
15.6.1.2.2.8. Glioblastoma Patient
15.6.1.2.2.9. Huntington's Disease (HD) Patient
15.6.1.2.2.10. Legg-Calve-Perthes Syndrome Patient
15.6.1.2.2.11. Mucopolysaccharidosis Patient
15.6.1.2.2.12. Neurofibromatosis Patient
15.6.1.2.2.13. Parkinson's Disease Patient
15.6.1.2.2.14. Psoriasis Patient
15.6.1.2.2.15. Rheumatoid Arthritis Patient
15.6.1.2.2.16. Systemic Lupus Erythematosus (SLE)
15.6.1.2.2.17. Transverse Myelitis Patient
15.6.1.2.2.18. Others
15.6.1.2.3. Serum-free Fibroblast Culture Medium
15.6.1.3. Saudi Arabia Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
15.6.1.3.1. Adults
15.6.1.3.2. Neonatal
15.6.1.4. Saudi Arabia Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.1.4.1. Hospitals
15.6.1.4.2. Clinics
15.6.1.4.3. Research and Academic Institutes
15.6.1.4.4. Others
15.6.2. UAE
15.6.2.1. UAE Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
15.6.2.1.1. Human Dermal Fibroblasts
15.6.2.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
15.6.2.1.3. Others
15.6.2.2. UAE Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
15.6.2.2.1. Tissue Specific Fibroblasts
15.6.2.2.1.1. Skin
15.6.2.2.1.2. Mammary
15.6.2.2.1.3. Lung
15.6.2.2.1.4. Kidney
15.6.2.2.1.5. Muscle
15.6.2.2.1.6. Others
15.6.2.2.2. Disease-specific Fibroblasts
15.6.2.2.2.1. Astrocytoma
15.6.2.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
15.6.2.2.2.3. Wound Healing
15.6.2.2.2.4. Arteriovenous Malformation (AVM) Patient
15.6.2.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
15.6.2.2.2.6. Diabetes
15.6.2.2.2.7. Guillain-Barre Syndrome (GBS) Patient
15.6.2.2.2.8. Glioblastoma Patient
15.6.2.2.2.9. Huntington's Disease (HD) Patient
15.6.2.2.2.10. Legg-Calve-Perthes Syndrome Patient
15.6.2.2.2.11. Mucopolysaccharidosis Patient
15.6.2.2.2.12. Neurofibromatosis Patient
15.6.2.2.2.13. Parkinson's Disease Patient
15.6.2.2.2.14. Psoriasis Patient
15.6.2.2.2.15. Rheumatoid Arthritis Patient
15.6.2.2.2.16. Systemic Lupus Erythematosus (SLE)
15.6.2.2.2.17. Transverse Myelitis Patient
15.6.2.2.2.18. Others
15.6.2.2.3. Serum-free Fibroblast Culture Medium
15.6.2.3. UAE Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
15.6.2.3.1. Adults
15.6.2.3.2. Neonatal
15.6.2.4. UAE Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.2.4.1. Hospitals
15.6.2.4.2. Clinics
15.6.2.4.3. Research and Academic Institutes
15.6.2.4.4. Others
15.6.3. Egypt
15.6.3.1. Egypt Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
15.6.3.1.1. Human Dermal Fibroblasts
15.6.3.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
15.6.3.1.3. Others
15.6.3.2. Egypt Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
15.6.3.2.1. Tissue Specific Fibroblasts
15.6.3.2.1.1. Skin
15.6.3.2.1.2. Mammary
15.6.3.2.1.3. Lung
15.6.3.2.1.4. Kidney
15.6.3.2.1.5. Muscle
15.6.3.2.1.6. Others
15.6.3.2.2. Disease-specific Fibroblasts
15.6.3.2.2.1. Astrocytoma
15.6.3.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
15.6.3.2.2.3. Wound Healing
15.6.3.2.2.4. Arteriovenous Malformation (AVM) Patient
15.6.3.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
15.6.3.2.2.6. Diabetes
15.6.3.2.2.7. Guillain-Barre Syndrome (GBS) Patient
15.6.3.2.2.8. Glioblastoma Patient
15.6.3.2.2.9. Huntington's Disease (HD) Patient
15.6.3.2.2.10. Legg-Calve-Perthes Syndrome Patient
15.6.3.2.2.11. Mucopolysaccharidosis Patient
15.6.3.2.2.12. Neurofibromatosis Patient
15.6.3.2.2.13. Parkinson's Disease Patient
15.6.3.2.2.14. Psoriasis Patient
15.6.3.2.2.15. Rheumatoid Arthritis Patient
15.6.3.2.2.16. Systemic Lupus Erythematosus (SLE)
15.6.3.2.2.17. Transverse Myelitis Patient
15.6.3.2.2.18. Others
15.6.3.2.3. Serum-free Fibroblast Culture Medium
15.6.3.3. Egypt Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
15.6.3.3.1. Adults
15.6.3.3.2. Neonatal
15.6.3.4. Egypt Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.3.4.1. Hospitals
15.6.3.4.2. Clinics
15.6.3.4.3. Research and Academic Institutes
15.6.3.4.4. Others
15.6.4. Kuwait
15.6.4.1. Kuwait Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
15.6.4.1.1. Human Dermal Fibroblasts
15.6.4.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
15.6.4.1.3. Others
15.6.4.2. Kuwait Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
15.6.4.2.1. Tissue Specific Fibroblasts
15.6.4.2.1.1. Skin
15.6.4.2.1.2. Mammary
15.6.4.2.1.3. Lung
15.6.4.2.1.4. Kidney
15.6.4.2.1.5. Muscle
15.6.4.2.1.6. Others
15.6.4.2.2. Disease-specific Fibroblasts
15.6.4.2.2.1. Astrocytoma
15.6.4.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
15.6.4.2.2.3. Wound Healing
15.6.4.2.2.4. Arteriovenous Malformation (AVM) Patient
15.6.4.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
15.6.4.2.2.6. Diabetes
15.6.4.2.2.7. Guillain-Barre Syndrome (GBS) Patient
15.6.4.2.2.8. Glioblastoma Patient
15.6.4.2.2.9. Huntington's Disease (HD) Patient
15.6.4.2.2.10. Legg-Calve-Perthes Syndrome Patient
15.6.4.2.2.11. Mucopolysaccharidosis Patient
15.6.4.2.2.12. Neurofibromatosis Patient
15.6.4.2.2.13. Parkinson's Disease Patient
15.6.4.2.2.14. Psoriasis Patient
15.6.4.2.2.15. Rheumatoid Arthritis Patient
15.6.4.2.2.16. Systemic Lupus Erythematosus (SLE)
15.6.4.2.2.17. Transverse Myelitis Patient
15.6.4.2.2.18. Others
15.6.4.2.3. Serum-free Fibroblast Culture Medium
15.6.4.3. Kuwait Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
15.6.4.3.1. Adults
15.6.4.3.2. Neonatal
15.6.4.4. Kuwait Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.4.4.1. Hospitals
15.6.4.4.2. Clinics
15.6.4.4.3. Research and Academic Institutes
15.6.4.4.4. Others
15.6.5. South Africa
15.6.5.1. South Africa Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
15.6.5.1.1. Human Dermal Fibroblasts
15.6.5.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
15.6.5.1.3. Others
15.6.5.2. South Africa Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
15.6.5.2.1. Tissue Specific Fibroblasts
15.6.5.2.1.1. Skin
15.6.5.2.1.2. Mammary
15.6.5.2.1.3. Lung
15.6.5.2.1.4. Kidney
15.6.5.2.1.5. Muscle
15.6.5.2.1.6. Others
15.6.5.2.2. Disease-specific Fibroblasts
15.6.5.2.2.1. Astrocytoma
15.6.5.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
15.6.5.2.2.3. Wound Healing
15.6.5.2.2.4. Arteriovenous Malformation (AVM) Patient
15.6.5.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
15.6.5.2.2.6. Diabetes
15.6.5.2.2.7. Guillain-Barre Syndrome (GBS) Patient
15.6.5.2.2.8. Glioblastoma Patient
15.6.5.2.2.9. Huntington's Disease (HD) Patient
15.6.5.2.2.10. Legg-Calve-Perthes Syndrome Patient
15.6.5.2.2.11. Mucopolysaccharidosis Patient
15.6.5.2.2.12. Neurofibromatosis Patient
15.6.5.2.2.13. Parkinson's Disease Patient
15.6.5.2.2.14. Psoriasis Patient
15.6.5.2.2.15. Rheumatoid Arthritis Patient
15.6.5.2.2.16. Systemic Lupus Erythematosus (SLE)
15.6.5.2.2.17. Transverse Myelitis Patient
15.6.5.2.2.18. Others
15.6.5.2.3. Serum-free Fibroblast Culture Medium
15.6.5.3. South Africa Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
15.6.5.3.1. Adults
15.6.5.3.2. Neonatal
15.6.5.4. South Africa Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.5.4.1. Hospitals
15.6.5.4.2. Clinics
15.6.5.4.3. Research and Academic Institutes
15.6.5.4.4. Others
15.6.6. Rest of Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
15.6.6.1.1. Human Dermal Fibroblasts
15.6.6.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
15.6.6.1.3. Others
15.6.6.2. Rest of Middle East & Africa Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
15.6.6.2.1. Tissue Specific Fibroblasts
15.6.6.2.1.1. Skin
15.6.6.2.1.2. Mammary
15.6.6.2.1.3. Lung
15.6.6.2.1.4. Kidney
15.6.6.2.1.5. Muscle
15.6.6.2.1.6. Others
15.6.6.2.2. Disease-specific Fibroblasts
15.6.6.2.2.1. Astrocytoma
15.6.6.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
15.6.6.2.2.3. Wound Healing
15.6.6.2.2.4. Arteriovenous Malformation (AVM) Patient
15.6.6.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
15.6.6.2.2.6. Diabetes
15.6.6.2.2.7. Guillain-Barre Syndrome (GBS) Patient
15.6.6.2.2.8. Glioblastoma Patient
15.6.6.2.2.9. Huntington's Disease (HD) Patient
15.6.6.2.2.10. Legg-Calve-Perthes Syndrome Patient
15.6.6.2.2.11. Mucopolysaccharidosis Patient
15.6.6.2.2.12. Neurofibromatosis Patient
15.6.6.2.2.13. Parkinson's Disease Patient
15.6.6.2.2.14. Psoriasis Patient
15.6.6.2.2.15. Rheumatoid Arthritis Patient
15.6.6.2.2.16. Systemic Lupus Erythematosus (SLE)
15.6.6.2.2.17. Transverse Myelitis Patient
15.6.6.2.2.18. Others
15.6.6.2.3. Serum-free Fibroblast Culture Medium
15.6.6.3. Rest of Middle East & Africa Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
15.6.6.3.1. Adults
15.6.6.3.2. Neonatal
15.6.6.4. Rest of Middle East & Africa Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.6.4.1. Hospitals
15.6.6.4.2. Clinics
15.6.6.4.3. Research and Academic Institutes
15.6.6.4.4. Others
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Product Type
15.7.3. By Type
15.7.4. By Application
15.7.5. By End Users
16. Latin America Fibroblast Cells Market Analysis and Forecasts, 2022 - 2030
16.1. Overview
16.1.1. Latin America Fibroblast Cells Market Revenue (US$ Mn)
16.2. Latin America Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
16.2.1. Human Dermal Fibroblasts
16.2.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
16.2.3. Others
16.3. Latin America Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
16.3.1. Tissue Specific Fibroblasts
16.3.1.1. Skin
16.3.1.2. Mammary
16.3.1.3. Lung
16.3.1.4. Kidney
16.3.1.5. Muscle
16.3.1.6. Others
16.3.2. Disease-specific Fibroblasts
16.3.2.1. Astrocytoma
16.3.2.2. Amyotrophic Lateral Sclerosis (ALS)
16.3.2.3. Wound Healing
16.3.2.4. Arteriovenous Malformation (AVM) Patient
16.3.2.5. Duchenne Muscular Dystrophy (DMD) Patient
16.3.2.6. Diabetes
16.3.2.7. Guillain-Barre Syndrome (GBS) Patient
16.3.2.8. Glioblastoma Patient
16.3.2.9. Huntington's Disease (HD) Patient
16.3.2.10. Legg-Calve-Perthes Syndrome Patient
16.3.2.11. Mucopolysaccharidosis Patient
16.3.2.12. Neurofibromatosis Patient
16.3.2.13. Parkinson's Disease Patient
16.3.2.14. Psoriasis Patient
16.3.2.15. Rheumatoid Arthritis Patient
16.3.2.16. Systemic Lupus Erythematosus (SLE)
16.3.2.17. Transverse Myelitis Patient
16.3.2.18. Others
16.3.3. Serum-free Fibroblast Culture Medium
16.4. Latin America Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
16.4.1. Adults
16.4.2. Neonatal
16.5. Latin America Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
16.5.1. Hospitals
16.5.2. Clinics
16.5.3. Research and Academic Institutes
16.5.4. Others
16.6. Latin America Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
16.6.1.1.1. Human Dermal Fibroblasts
16.6.1.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
16.6.1.1.3. Others
16.6.1.2. Brazil Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
16.6.1.2.1. Tissue Specific Fibroblasts
16.6.1.2.1.1. Skin
16.6.1.2.1.2. Mammary
16.6.1.2.1.3. Lung
16.6.1.2.1.4. Kidney
16.6.1.2.1.5. Muscle
16.6.1.2.1.6. Others
16.6.1.2.2. Disease-specific Fibroblasts
16.6.1.2.2.1. Astrocytoma
16.6.1.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
16.6.1.2.2.3. Wound Healing
16.6.1.2.2.4. Arteriovenous Malformation (AVM) Patient
16.6.1.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
16.6.1.2.2.6. Diabetes
16.6.1.2.2.7. Guillain-Barre Syndrome (GBS) Patient
16.6.1.2.2.8. Glioblastoma Patient
16.6.1.2.2.9. Huntington's Disease (HD) Patient
16.6.1.2.2.10. Legg-Calve-Perthes Syndrome Patient
16.6.1.2.2.11. Mucopolysaccharidosis Patient
16.6.1.2.2.12. Neurofibromatosis Patient
16.6.1.2.2.13. Parkinson's Disease Patient
16.6.1.2.2.14. Psoriasis Patient
16.6.1.2.2.15. Rheumatoid Arthritis Patient
16.6.1.2.2.16. Systemic Lupus Erythematosus (SLE)
16.6.1.2.2.17. Transverse Myelitis Patient
16.6.1.2.2.18. Others
16.6.1.2.3. Serum-free Fibroblast Culture Medium
16.6.1.3. Brazil Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
16.6.1.3.1. Adults
16.6.1.3.2. Neonatal
16.6.1.4. Brazil Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.1.4.1. Hospitals
16.6.1.4.2. Clinics
16.6.1.4.3. Research and Academic Institutes
16.6.1.4.4. Others
16.6.2. Argentina
16.6.2.1. Argentina Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
16.6.2.1.1. Human Dermal Fibroblasts
16.6.2.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
16.6.2.1.3. Others
16.6.2.2. Argentina Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
16.6.2.2.1. Tissue Specific Fibroblasts
16.6.2.2.1.1. Skin
16.6.2.2.1.2. Mammary
16.6.2.2.1.3. Lung
16.6.2.2.1.4. Kidney
16.6.2.2.1.5. Muscle
16.6.2.2.1.6. Others
16.6.2.2.2. Disease-specific Fibroblasts
16.6.2.2.2.1. Astrocytoma
16.6.2.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
16.6.2.2.2.3. Wound Healing
16.6.2.2.2.4. Arteriovenous Malformation (AVM) Patient
16.6.2.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
16.6.2.2.2.6. Diabetes
16.6.2.2.2.7. Guillain-Barre Syndrome (GBS) Patient
16.6.2.2.2.8. Glioblastoma Patient
16.6.2.2.2.9. Huntington's Disease (HD) Patient
16.6.2.2.2.10. Legg-Calve-Perthes Syndrome Patient
16.6.2.2.2.11. Mucopolysaccharidosis Patient
16.6.2.2.2.12. Neurofibromatosis Patient
16.6.2.2.2.13. Parkinson's Disease Patient
16.6.2.2.2.14. Psoriasis Patient
16.6.2.2.2.15. Rheumatoid Arthritis Patient
16.6.2.2.2.16. Systemic Lupus Erythematosus (SLE)
16.6.2.2.2.17. Transverse Myelitis Patient
16.6.2.2.2.18. Others
16.6.2.2.3. Serum-free Fibroblast Culture Medium
16.6.2.3. Argentina Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
16.6.2.3.1. Adults
16.6.2.3.2. Neonatal
16.6.2.4. Argentina Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.2.4.1. Hospitals
16.6.2.4.2. Clinics
16.6.2.4.3. Research and Academic Institutes
16.6.2.4.4. Others
16.6.3. Rest of Latin America
16.6.3.1. Rest of Latin America Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Product Type
16.6.3.1.1. Human Dermal Fibroblasts
16.6.3.1.2. Dermal Fibroblasts matched with Subcutaneous Preadipocytes
16.6.3.1.3. Others
16.6.3.2. Rest of Latin America Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Type
16.6.3.2.1. Tissue Specific Fibroblasts
16.6.3.2.1.1. Skin
16.6.3.2.1.2. Mammary
16.6.3.2.1.3. Lung
16.6.3.2.1.4. Kidney
16.6.3.2.1.5. Muscle
16.6.3.2.1.6. Others
16.6.3.2.2. Disease-specific Fibroblasts
16.6.3.2.2.1. Astrocytoma
16.6.3.2.2.2. Amyotrophic Lateral Sclerosis (ALS)
16.6.3.2.2.3. Wound Healing
16.6.3.2.2.4. Arteriovenous Malformation (AVM) Patient
16.6.3.2.2.5. Duchenne Muscular Dystrophy (DMD) Patient
16.6.3.2.2.6. Diabetes
16.6.3.2.2.7. Guillain-Barre Syndrome (GBS) Patient
16.6.3.2.2.8. Glioblastoma Patient
16.6.3.2.2.9. Huntington's Disease (HD) Patient
16.6.3.2.2.10. Legg-Calve-Perthes Syndrome Patient
16.6.3.2.2.11. Mucopolysaccharidosis Patient
16.6.3.2.2.12. Neurofibromatosis Patient
16.6.3.2.2.13. Parkinson's Disease Patient
16.6.3.2.2.14. Psoriasis Patient
16.6.3.2.2.15. Rheumatoid Arthritis Patient
16.6.3.2.2.16. Systemic Lupus Erythematosus (SLE)
16.6.3.2.2.17. Transverse Myelitis Patient
16.6.3.2.2.18. Others
16.6.3.2.3. Serum-free Fibroblast Culture Medium
16.6.3.3. Rest of Latin America Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By Application
16.6.3.3.1. Adults
16.6.3.3.2. Neonatal
16.6.3.4. Rest of Latin America Fibroblast Cells Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.3.4.1. Hospitals
16.6.3.4.2. Clinics
16.6.3.4.3. Research and Academic Institutes
16.6.3.4.4. Others
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Product Type
16.7.3. By Type
16.7.4. By Application
16.7.5. By End Users
17. Competitive Benchmarking
17.1. Market Share Analysis, 2021
17.2. Global Presence and Growth Strategies
17.2.1. Mergers and Acquisitions
17.2.2. Product Launches
17.2.3. Investments Trends
17.2.4. R&D Initiatives
18. Player Profiles
18.1. Axol Bioscience Ltd.
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. Cell Applications, Inc.
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. FibroGenesis
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. Merck KGaA, Darmstadt
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. Novus Biologicals
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. Ohr Pharma + NewBase Therapeuitcs
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. ThermoFisher Scientific
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. ZenBio, Inc.
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. Other Market Participants
19. Key Findings
Note: This
ToC is tentative and can be changed according to the research study conducted
during the course of report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
